Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study

被引：2
|
作者：
Wang Feng [1 ]
Wang Junsheng [2 ]
Wu Tao [2 ]
Hong Yonggui [2 ]
Meng Xiangrui [1 ]
Ren Zhonghai [3 ]
Guo Yanzhen [4 ]
Yang Xiuli [5 ]
Shi Pei [5 ]
Yang Jiamei [6 ]
Fan Qingxia [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[2] AnYang Tumor Hosp, Anyang, Peoples R China
[3] Nanyang Cent Hosp, Nanyang, Peoples R China
[4] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[5] Nanyang Med Coll, Affiliated Hosp 1, Nanyang, Peoples R China
[6] Zhengzhou Univ, Affiliated Hosp 2, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.215
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
215
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Preoperative camrelizumab combined with chemotherapy for borderline resectable esophageal squamous cell carcinoma (BRES-1): A single-arm, open-label, phase II study.
    Yang, Hang
    Zhang, Guoqing
    Li, Xiangnan
    Jiao, Jia
    Guo, Yanan
    Zhang, Yan
    Hou, Zhichao
    Huang, Qi
    Zhao, Jia
    Li, Jindong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 360 - 360
  • [22] Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study
    Zhang, Yan
    Xu, Junying
    Wang, Qiong
    Ling, Guohong
    Mao, Yong
    Cai, Maohuai
    Yang, Yang
    Mei, Jingfeng
    Han, Zhengxiang
    Feng, Jifeng
    Wu, Yuan
    Shi, Lin
    Wen, Shaodi
    Shen, Bo
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (11)
  • [23] Neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma with camrelizumab, albumin-paclitaxel, carboplatin and apatinib (GASTO-1093): A single-arm, open-label, phase 2 trial
    Cheng, Chao
    Yang, Weixiong
    Yeung, Sai-Ching Jim
    Xing, Xiangbin
    Chen, Wenfang
    Bao, Yong
    Feng, Shiting
    Peng, Fang
    Wang, Xiaoyan
    Zhang, Shuishen
    Zeng, Bo
    Liu, Zhenguo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Neoadjuvant camrelizumab followed by concurrent camrelizumab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, phase II study
    Sheng, Yinliang
    Meng, Xiangrui
    Zhang, Chunyang
    Shan, Zhengzheng
    Li, Feng
    Wu, Bin
    Xu, Mengli
    Li, Aijia
    Guan, Lulu
    Chen, Lidong
    Sun, Shuzhen
    Ma, Yihui
    Lu, Taiying
    Zhao, Song
    Fan, Qingxia
    Qi, Yu
    Wang, Feng
    JOURNAL OF THORACIC DISEASE, 2024, 16 (08) : 5337 - 5347
  • [25] Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial
    Gong, Lei
    Yang, Yueyang
    Zhang, Hongdian
    Qiao, Yufeng
    Wang, Haitong
    Ren, Peng
    Tang, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
    Liu, Jun
    Yang, Yang
    Liu, Zhichao
    Fu, Xiaolong
    Cai, Xiaoyue
    Li, Hongxuan
    Zhu, Li
    Shen, Yan
    Zhang, Hong
    Sun, Yifeng
    Chen, Hezhong
    Yu, Bentong
    Zhang, Renquan
    Shao, Jinchen
    Zhang, Ming
    Li, Zhigang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
  • [27] Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
    Hu, Zhihuang
    Sun, Si
    Zhao, Xinmin
    Yu, Hui
    Wu, Xianghua
    Wang, Jialei
    Chang, Jianhua
    Wang, Huijie
    ONCOLOGIST, 2022, 27 (04): : 253 - +
  • [28] Camrelizumab monotherapy or plus apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A single-arm, open-label, multicenter, phase II study
    Zhao, M.
    Liu, X.
    Yuan, C.
    Zheng, W.
    Zhang, D.
    Long, Q.
    Li, J.
    Han, T.
    Xu, L.
    Li, H.
    Li, X.
    Shi, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S36 - S37
  • [29] Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Non-Squamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
    Ren, S.
    He, J.
    Fang, Y.
    Chen, G.
    Ma, Z.
    Chen, J.
    Guo, R.
    Lin, X.
    Yao, Y.
    Wu, G.
    Wang, Q.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S924 - S924
  • [30] Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A for Nonrandomized, Open-label, Phase II Trial
    Xu, Jianming
    Shen, Jie
    Gu, Shanzhi
    Zhang, Yun
    Wu, Lihua
    Wu, Jian
    Shao, Guoliang
    Zhang, Yanqiao
    Xu, Li
    Yin, Tao
    Liu, Jingfeng
    Ren, Zhenggang
    Xiong, Jianping
    Mao, Xianhai
    Zhang, Ling
    Yang, Jiayin
    Li, Lequn
    Chen, Xiaoming
    Wang, Zhiming
    Gu, Kangsheng
    Chen, Xi
    Pan, Zhanyu
    Ma, Kuansheng
    Zhou, Xinmin
    Yu, Zujiang
    Li, Enxiao
    Yin, Guowen
    Zhang, Xiao
    Wang, Shuni
    Wang, Quanren
    CLINICAL CANCER RESEARCH, 2021, 27 (04) : 1003 - 1011
12345